Thursday, April 25, 2019
Spotlight Company - Avacta Bio
Check out this new approach to bispecific molecule design by Avacta Bio out of Cambridge. They are building single chain peptides with target binding regions designed through phage display screening libraries.
This technology can be used to target single antigens, bi-specifics, and checkpoint inhibitor targets. Beyond that, they are applying this to ADCs to make what they call TMAC molecules.
Their idea is that a small peptide chain can be manufactured more easily while still providing all of the advantages of a bispecific antibody therapy.
It looks interesting, but will the body tolerate this molecule for long periods of time, or is there something evolved into an antibody structure which cannot be mimicked with a peptide chain approach?